Evidence and Uncertainties Surrounding Renin-Guided Medical Therapy for Primary Aldosteronism
American Journal of Hypertension · 2023
DOI: 10.1093/ajh/hpad034 ↗Kurz gefasst
Editorial in der Zeitschrift American Journal of Hypertension, 2023. Verfasst von Swapnil Hiremath und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, University of Ottawa, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Hypertension, Hyperaldosteronism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canadian Institutes of Health Research, Institute of Nutrition, Metabolism and Diabetes.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Nephrology, University of Ottawa, Ottawa, Ontario, Canada.
- Ottawa Hospital Research Institute, Clinical Epidemiology Program, University of Ottawa, Ottawa, Ontario, Canada.
ORCID-Profile: Gregory L Hundemer
Förderung
- CIHR
- Canadian Institutes of Health Research
- Institute of Nutrition, Metabolism and Diabetes
- Kidney Foundation of Canada
- Lorna Jocelyn Wood Chair for Kidney Research
Zitieren
APA
Hiremath, S., & Hundemer, G. L. (2023). Evidence and Uncertainties Surrounding Renin-Guided Medical Therapy for Primary Aldosteronism. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpad034
Vancouver
Hiremath S, Hundemer GL. Evidence and Uncertainties Surrounding Renin-Guided Medical Therapy for Primary Aldosteronism. American Journal of Hypertension. 2023. doi:10.1093/ajh/hpad034
BibTeX
@article{Hiremath2023,
author = {Hiremath, Swapnil and Hundemer, Gregory L},
title = {Evidence and Uncertainties Surrounding Renin-Guided Medical Therapy for Primary Aldosteronism},
journal = {American Journal of Hypertension},
year = {2023},
doi = {10.1093/ajh/hpad034}
}
EUVIMED